# Cardiovascular Therapeutics Domain: Advanced Medicine · 252 papers indexed · newest 2026-10-12 Lipoprotein(a)-lowering drugs, siRNA and gene-editing approaches to LDL cholesterol, CETP inhibition and other cardiovascular advances. Key concepts: cardiovascular ## Most influential - **[Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease](https://space-kitty.com/papers/doi:10.1056/nejmoa1615664)**. Marc Steven Sabatine, Robert Patrick Giugliano, ANTHONY C. KEECH et al. · 2017 · New England Journal of Medicine (doi:10.1056/nejmoa1615664 · 6,134 citations). Source: - **[Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel](https://space-kitty.com/papers/doi:10.1093/eurheartj/ehx144)**. Brian A. Ference, Henry N. Ginsberg, Ian M Graham et al. · 2017 · European Heart Journal (doi:10.1093/eurheartj/ehx144 · 3,961 citations). Source: - **[Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome](https://space-kitty.com/papers/doi:10.1056/nejmoa1801174)**. Gregory G. Schwartz, Philippe Gabríel Steg, Michael J. Szarek et al. · 2018 · New England Journal of Medicine (doi:10.1056/nejmoa1801174 · 3,628 citations). Source: - **[Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia](https://space-kitty.com/papers/doi:10.1056/nejmoa1812792)**. Deepak L. Bhatt, Philippe Gabríel Steg, Michael J. Miller et al. · 2018 · New England Journal of Medicine (doi:10.1056/nejmoa1812792 · 3,316 citations). Source: - **[Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events](https://space-kitty.com/papers/doi:10.1056/nejmoa1501031)**. Jennifer G. Robinson, Michel Farnier, Michel Krempf et al. · 2015 · New England Journal of Medicine (doi:10.1056/nejmoa1501031 · 2,295 citations). Source: - **[Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement](https://space-kitty.com/papers/doi:10.1093/eurheartj/ehac361)**. Florian Kronenberg, Samia Mora, Erik S.G. Stroes et al. · 2022 · European Heart Journal (doi:10.1093/eurheartj/ehac361 · 1,448 citations). Source: - **[Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions](https://space-kitty.com/papers/doi:10.1001/jama.2016.13985)**. Michael G. Silverman, Brian A. Ference, Kyungah Im et al. · 2016 · JAMA (doi:10.1001/jama.2016.13985 · 1,482 citations). Source: - **[Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial](https://space-kitty.com/papers/doi:10.1016/s2213-8587(22)00353-9)**. Ray KK, Troquay RPT, Visseren FLJ et al. · 2023 · The lancet. Diabetes & endocrinology (doi:10.1016/s2213-8587(22)00353-9 · 257 citations). Source: > Introduction Whether long-term treatment with the twice-yearly, siRNA therapeutic inclisiran, which reduces hepatic production of proprotein convertase subtilisin/kexin type 9 (PCSK9), results in sustained reductions in LDL cholesterol with an acceptable safety profile is not known. The aim of this study was to assess the effect of long-term dosing of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol. Methods ORION-3 was a 4-year open-label extension study of the placebo-controlled, phase 2 ORION-1 trial, conducted at 52 sites across five countries. Patients wit… > _Abstract excerpt by Ray KK et al., CC-BY, https://doi.org/10.1016/s2213-8587(22)00353-9; truncated._ - **[Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management](https://space-kitty.com/papers/doi:10.1093/eurheartj/ehr112)**. M. John Chapman, Henry N. Ginsberg, Pierre Amarenco et al. · 2011 · European Heart Journal (doi:10.1093/eurheartj/ehr112 · 1,227 citations). Source: - **[Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside](https://space-kitty.com/papers/doi:10.1038/s41392-023-01690-3)**. Bao X, Liang Y, Chang H et al. · 2024 · Signal transduction and targeted therapy (doi:10.1038/s41392-023-01690-3 · 145 citations). Source: > Proprotein convertase subtilisin/kexin type 9 (PCSK9) has evolved as a pivotal enzyme in lipid metabolism and a revolutionary therapeutic target for hypercholesterolemia and its related cardiovascular diseases (CVD). This comprehensive review delineates the intricate roles and wide-ranging implications of PCSK9, extending beyond CVD to emphasize its significance in diverse physiological and pathological states, including liver diseases, infectious diseases, autoimmune disorders, and notably, cancer. Our exploration offers insights into the interaction between PCSK9 and low-density lipoprotein … > _Abstract excerpt by Bao X et al., CC-BY, https://doi.org/10.1038/s41392-023-01690-3; truncated._ - **[A Test in Context: Lipoprotein(a)](https://space-kitty.com/papers/doi:10.1016/j.jacc.2016.11.042)**. Sotirios Tsimikas · 2017 · Journal of the American College of Cardiology (doi:10.1016/j.jacc.2016.11.042 · 1,136 citations). Source: - **[Lipoprotein(a) Reduction in Persons with Cardiovascular Disease](https://space-kitty.com/papers/doi:10.1056/nejmoa1905239)**. Sotirios Tsimikas, Ewa Karwatowska‐Prokopczuk, Ioanna Gouni‐Berthold et al. · 2020 · New England Journal of Medicine (doi:10.1056/nejmoa1905239 · 1,090 citations). Source: - **[Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society](https://space-kitty.com/papers/doi:10.1093/eurheartj/ehab551)**. Henry N. Ginsberg, Chris J. Packard, M. John Chapman et al. · 2021 · European Heart Journal (doi:10.1093/eurheartj/ehab551 · 978 citations). Source: - **[American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease](https://space-kitty.com/papers/doi:10.4158/ep171764.appgl)**. Paul S. Jellinger, Yehuda Handelsman, Paul D. Rosenblit et al. · 2017 · Endocrine Practice (doi:10.4158/ep171764.appgl · 1,093 citations). Source: - **[2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults](https://space-kitty.com/papers/doi:10.1016/j.cjca.2021.03.016)**. Glen J. Pearson, George Thanassoulis, Todd J. Anderson et al. · 2021 · Canadian Journal of Cardiology (doi:10.1016/j.cjca.2021.03.016 · 848 citations). Source: ## Newest - **[Effectiveness and safety of target-specific RNA-based lipid-lowering therapies: A systematic review and meta-analysis of randomized controlled trials](https://space-kitty.com/papers/doi:10.1016/j.ejphar.2026.179420)**. Widjaja JS, Adji AS, Baraja A et al. · 2026 · European journal of pharmacology (doi:10.1016/j.ejphar.2026.179420). Source: - **[Lipoprotein(a) reduction with PCSK9-targeting pharmacotherapy: A prospective real-world registry study](https://space-kitty.com/papers/doi:10.1016/j.atherosclerosis.2026.121912)**. Kafol J, Fras Z, Novakovic M et al. · 2026 · Atherosclerosis (doi:10.1016/j.atherosclerosis.2026.121912). Source: - **[Simulation and Analysis of Solute Transport in Multi-Lymphangion Lymphatic Vessels](https://space-kitty.com/papers/arxiv:2609.25964)**. Timo Jakumeit, Thiha Aung, Robert Schober et al. · 2026 (arXiv:2609.25964). Source: - **[Serial Coronary Plaque Composition After Inclisiran Initiation Assessed by Automated CCTA: A Retrospective Pilot Study](https://space-kitty.com/papers/doi:10.3390/diagnostics16183009)**. Kawada K, Suzuki M, Mochizuki J et al. · 2026 · Diagnostics (Basel, Switzerland) (doi:10.3390/diagnostics16183009). Source: - **[The 2026 ACC/AHA Dyslipidemia Guideline: A Critical and Transatlantic Perspective on Personalized Lipid Management](https://space-kitty.com/papers/doi:10.3390/life16091470)**. Sabouret P, Mafrica D, Giamundo DM et al. · 2026 · Life (Basel, Switzerland) (doi:10.3390/life16091470). Source: - **[Prediction of inclisiran efficacy in patients with established atherosclerotic cardiovascular disease: the SIRIUS in-silico modelling of cardiovascular outcomes](https://space-kitty.com/papers/doi:10.1093/eurjpc/zwaf783)**. Angoulvant D, Peyronnet E, Cariou B et al. · 2026 · European journal of preventive cardiology (doi:10.1093/eurjpc/zwaf783 · 6 citations). Source: - **[The Utilization of Inclisiran for the Optimization of Lipid Management in People Living with HIV: A Clinical Case Series and Comprehensive Review](https://space-kitty.com/papers/doi:10.3390/reports9030284)**. Petrakis V, Panopoulou M, Grapsa A et al. · 2026 · Reports (MDPI) (doi:10.3390/reports9030284). Source: - **[A New Option for the Management of Dyslipidemias: Advances in Research on the Small Interfering RNA Drug Inclisiran](https://space-kitty.com/papers/doi:10.31083/rcm48237)**. Wu X, Zhang J · 2026 · Reviews in cardiovascular medicine (doi:10.31083/rcm48237). Source: - **[Inclisiran-induced LDL-cholesterol reduction with and without concomitant statin therapy: a real-world analysis](https://space-kitty.com/papers/doi:10.1186/s12872-026-06429-w)**. Seidel M, Seibert FS, Anft M et al. · 2026 · BMC cardiovascular disorders (doi:10.1186/s12872-026-06429-w). Source: - **[HPS-4/TIMI 65/ORION-4: A double-blind randomized placebo-controlled trial assessing the effects of inclisiran on clinical outcomes among people with atherosclerotic cardiovascular disease: Trial design, recruitment, and baseline characteristics](https://space-kitty.com/papers/doi:10.1016/j.ahj.2026.107546)**. Mafham MM, Zayed MG, Collins R et al. · 2026 · American heart journal (doi:10.1016/j.ahj.2026.107546 · 16 citations). Source: ## Clinical trials - **[A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)](https://space-kitty.com/papers/nct:NCT06292013)**. Eli Lilly and Company · 2024 · ClinicalTrials.gov (NCT06292013). Source: - **[OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events](https://space-kitty.com/papers/nct:NCT07136012)**. Amgen · 2025 · ClinicalTrials.gov (NCT07136012). Source: - **[Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease](https://space-kitty.com/papers/nct:NCT05030428)**. Novartis Pharmaceuticals · 2021 · ClinicalTrials.gov (NCT05030428). Source: - **[An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)](https://space-kitty.com/papers/nct:NCT07517263)**. Novartis Pharmaceuticals · 2026 · ClinicalTrials.gov (NCT07517263). Source: - **[A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.](https://space-kitty.com/papers/nct:NCT05739383)**. Novartis Pharmaceuticals · 2023 · ClinicalTrials.gov (NCT05739383). Source: - **[A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease](https://space-kitty.com/papers/nct:NCT03705234)**. University of Oxford · 2018 · ClinicalTrials.gov (NCT03705234). Source: - **[Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease](https://space-kitty.com/papers/nct:NCT05202509)**. NewAmsterdam Pharma · 2022 · ClinicalTrials.gov (NCT05202509). Source: - **[Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial](https://space-kitty.com/papers/nct:NCT05581303)**. Amgen · 2022 · ClinicalTrials.gov (NCT05581303). Source: --- Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.